Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019708 · ClinicalTrials.gov registry record · Phase 1
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00019708: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00019708 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019708, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of geldanamycin analogue in treating patients who have advanced solid tumors or non-Hodgkin's lymphoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- DRUG tanespimycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1999-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019708
The ClinicalTrials.gov registry entry for NCT00019708 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tanespimycin is the first listed.
NCT00019708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019708 about?
NCT00019708 is a clinical study titled "Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma". Phase I trial to study the effectiveness of geldanamycin analogue in treating patients who have advanced solid tumors or non-Hodgkin's lymphoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00019708?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 1999-06.
What interventions are being tested in trial NCT00019708?
The interventions under investigation include: tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00019708?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.